Background Although advances in the treatment of myeloid neoplasms have led to improved patient survival, this improvement has been accompanied by an increased risk of second primary cancer (ie, the risk of another cancer after myeloid neoplasia). We aimed to assess bi-directional associations between myeloid cancers and other cancersie, development of second primary cancer in patients who have previously had myeloid cancer, and risks of myeloid neoplasia in patients who have previously had another cancer-to provide insight into possible mechanisms beyond side-effects of treatment and shared risk factors.
Introduction
All myeloid cancers originate from the same haemopoietic lineage and are characterised by excessive proliferation, abnormal self-renewal, and differentiation defects. 1, 2 The distinct clinical phenotypes are BCR-ABL1-negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythemia, myelofibrosis, chronic myeloid leukaemia, myelodysplastic syndrome, and acute myeloid leukaemia. Polycythaemia vera is char acterised by a high erythrocyte count, essential thrombocythaemia by a high platelet count, and myelofibrosis by bone marrow failure. Myelodysplastic syndrome is characterised by ineffective haemopoiesis, morphological dysplasia in haemopoietic cells, and cytopenia. 3 Although myeloproliferative neoplasm sub types are independent diseases, transformation from myeloproliferative disorders and myelodysplastic syn drome to acute myeloid leukaemia can occur. 2, 4 The causes of myeloid diseases are poorly understood and few risk factors have been identified. Known risk factors for acute myeloid leukaemia include exposure to ionising radiation, chemicals such as benzene, and cytotoxic chemotherapy. 2 For myelodysplastic syndrome risk factors include autoimmune disorders and immunological aber rations. [5] [6] [7] Several rare high penetrance mutations in cancer susceptibility genes-such as Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukaemia virus oncogene (MPL)-have been identified and are now incorporated in disease classification, for example for myeloproliferative neoplasms. 3, 8 Treatment for myelopro liferative disorders aims to reduce the risk of progression and has relied on compounds such as hydroxyurea, inhibiting DNA synthesis, and cytokine interferon alpha, which modulates immune and other functions; more recently specific JAK-2 inhibitors have been included in treatment. 9 Patients with acute myeloid leukaemia might receive induction treatment with DNA synthesis inhibitors, such as cytarabine and anthracycline, supple mented with hydroxyurea. Consolidation treatment could include cytarabine administration or bone marrow transplantation. Until tyrosine kinase inhibitors were introduced into the standard of care for BCR-ABL1-positive patients in about the year 2000, treatment for chronic myeloid leukaemia was hydroxycarbamide, interferon alpha, and allogeneic haemopoietic stem-cell transplantation, and still remains the standard treatment. 10 Treatment options for myelodysplastic syndrome, which depend on diagnostic findings and symptoms, can include multiple modalities. Treatment for first cancers might be an important risk factor for second primary cancers.
Recent advances in the management of all forms of myeloid cancers, including personalised approaches, have greatly improved patient survival. However, this increase in survival has been accompanied by an increase in the number of second primary cancers and other treatment-related complications, such as cardiovascular and neurological symptoms. 11 Several studies have estimated the risks of second primary cancers after myeloid cancer, but most have confined their analyses to acute myeloid leukaemia and chronic myeloid leukaemia, with scant available data for myeloproliferative neoplasms. 9, [12] [13] [14] [15] This gap in the literature seems to be largely because most cancer registries do not collect data on other myeloid cancers. To address this deficiency, we used data from the Swedish Cancer Registry to analyse all myeloid cancers and second primary cancers after myeloid cancers in Sweden, and myeloid cancers diagnosed as second primary cancers following the occurrence of any non-myeloid first cancer.
Methods

Study design and participants
The Swedish Family-Cancer Database includes data from the Swedish population, organised by families, and linked to the national Cancer Registry. The registry relies on compulsory notifications from clinicians who diagnose any neoplasm and separate notifications from pathologists and cytologists. It includes every individual registered as a resident in Sweden since 1932 with full parental histories. The database's coverage is estimated at more than 90% of all cancer diagnoses in Sweden, with more than 2 million cancers registered since 1958. 16 The registry counts tumours not patients, except in cases where a patient has more than one tumour of the skin or urinary tract diagnosed in the same topological area. To classify cancer types, the Swedish Cancer Registry has used International Classification of Disease (ICD)-7 since 1958, ICD-9 since 1987, SNOMED (ICD-O/2) since 1993, and ICD-O/3 since 2005. The degree of histological verification of myeloid cancers varies from 98% to
Research in context
Evidence before this study We searched PubMed with the search terms "second primary cancer after myeloid disease" and "myeloid disease diagnosed after cancer"; we also applied specific myeloid diseases as search terms. Furthermore, we reviewed the literature cited in the identified papers.
Added value of this study
The present study applied two novel approaches. Using data from 35 928 individuals with myeloid neoplasia registered with the Swedish Cancer Registry, we analysed risk of second primary cancer after all main types of primary myeloid cancer, including myelodysplastic syndrome, which had not previously been assessed in the context of relative risk for second primary cancer. Furthermore, we used bi-directional analysis to assess risk of second primary cancers after myeloid neoplasms, and risk of myeloid neoplasms after any of 32 cancers. Our findings showed that risks of myeloid neoplasms were associated with all haematological cancers. We showed that the increased risk of second primary cancers is not confined to a specific myeloid cancer, and that it is also increased after myelodysplastic syndrome. Bi-directional increases in risk were observed for nine myeloid neoplasia-cancer pairs. Upper aerodigestive tract cancer, squamous cell skin cancer, and non-Hodgkin lymphoma were the major second primary cancers following diagnosis of acute myeloid leukaemia, chronic myeloid leukaemia, myelodysplastic syndrome, and myeloproliferative neoplasm. The results suggest that new mechanisms, such as immune dysfunction, might contribute to bi-directional risks.
Implications of all available evidence
Increased risks of myeloid cancers after melanoma, squamous cell skin cancer, and kidney cancers, all of which are treated mainly by surgery, raise the possibility that immune dysfunction could be a contributing factor to second primary cancers in people who have had myeloid cancer, but this hypothesis requires further studies. Treatment for myeloid neoplasms has undergone many recent changes and therapeutic successes need to be weighed against side-effects, such as risk of second primary cancer.
100% for acute myeloid leukaemia and chronic myeloid leukaemia, to about 95% for polycythaemia vera and myelofibrosis. 17 An ad hoc study of the diagnostic accuracy of second neoplasms in the Swedish Cancer Registry found 98% of these to be correctly classified; no recorded second primary cancer was found to be a metastasis upon re-examination. 18 The Swedish Cancer Registry organises reported cancers as first, second, third primary cancer, and so on, and we followed this order. We included data from all patients whose first primary cancer was acute myeloid leukaemia, chronic myeloid leukaemia, myelodysplastic syndrome, polycythaemia vera, essential thrombo cythaemia, myelofibrosis, or myeloproliferative neoplasm (not otherwise specified) diagnosed between 1958 and 2015, and were analysed for the relative risk of second primary cancer. In assessing the relative risk of myeloid cancers as a second primary cancer, we included patients with any first primary cancer except leukaemia, to avoid dependency. We selected any of 32 cancers by the main categories of ICD-7. We used ICD-7 and ICD-O/2 codes to distinguish between different haematological cancers and subtypes. Myeloproliferative neoplasms were classified according to the 2016 WHO classification. Myeloproliferative neoplasm (not other wise specified), myelofibrosis, and myelodysplastic syndrome were distinguished in ICD-O/2, and included as distinct entities in the database from 1993. We excluded rare myeloproliferative neoplasms, such as chronic eosinophilic leukaemia and chronic neutrophilic leukaemia, from our subtype analysis. We did not include data from patients who developed myeloid disease after previous myeloid disease because of the potential for transformation between tumour types. The ICD codes used by the Swedish Cancer Registry do not specify treatment-related cancers, although the literature suggests that treatment-related cancers now account for 7% of acute myeloid leukaemia. 19 The study periods were constrained by the availability of data.
Outcomes and statistical analysis
Relative risks (RRs) for second primary cancers were assessed by means of incidence rate ratios, assuming that cancer diagnoses followed waiting time distribution, regressed over a fixed effects generalised Poisson model. Regression was assessed on case numbers scaled on person-years. This reduced case numbers as compared with the reference fractions in each person-year category.
Person-year calculation for the background population ensured large case numbers in each covariate band and met the large number assumption for the Poisson distribution. RRs for the second primary cancer were obtained by comparing incidence of that cancer type in the general Swedish population without previous diagnosis of cancer with the incidence of that cancer type as a second primary cancer in patients who had had myeloid cancer as a first primary cancer. Conversely, to consider myeloid cancers as second primary cancers, the incidence rates were compared against the incidence of the first primary myeloid neoplasm in the background population without a previous cancer diagnosis. These two types of analyses constituted the bi-directional or reciprocal analyses. Sex, age group, calendar-period, socioeconomic status, and residential area were regarded as potential confounders and were adjusted for in the regression model. Confidence intervals (CIs) were calculated for 5%, 1% and 0·1% level of significance.
All analyses were done with SAS (version 9.4) or R (version 3.3.4). The study was approved by the Ethical Committee of Lund University, Sweden, and conducted in accordance with the Declaration of Helsinki. Data are n (%) or median (IQR). Follow-up time is the duration of follow up between diagnosis of first primary cancer and diagnosis of second primary cancer. 
Role of the funding source
The funders had no role in the design or conduct of the study. KH had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Of the 35 928 patients recorded by the Swedish Cancer Registry with primary myeloid cancer between 1958 and 2015, 1405 men and 1226 women developed a second primary cancer with a median follow up of 4 years (table 1) . Acute myeloid leukaemia was the most common primary myeloid cancer (12 832 patients), but only 427 (3%) were diagnosed with a second primary cancer. Of 6636 patients with polycythemia vera, 916 (14%) were diagnosed with a second primary cancer (table 1) . Of the 940 811 other patients, 3873 (<1%) developed a myeloid cancer as a second primary cancer (table 2) , with a median follow up of 6 years. We did stratified risk analyses on second primary cancer incidence after myeloid neoplasia, stratifying by time, sex, age at first cancer diagnosis, and duration of follow up between diagnosis of first primary cancer and diagnosis of second primary cancer (appendix pp 2-5). No cases with myelodysplastic syndrome or myeloproliferative neoplasm (not otherwise specified) were recorded in the early study periods, as the coding system for identification of these cases started to be used in 1993 (appendix p 2). RRs for the second primary cancer did not differ between study periods (ie, 95% CIs were overlapping), with the exception of a high RR of 1·81 for myeloproliferative neoplasm between 1971 and 1985, partly caused by the high RR for essential thrombo cythaemia. Sex did not affect risk for second primary cancer (appendix p 3) but diagnosis with myeloid neoplasia below the age of 65 years was a strong risk modifier (increased risk), except in patients with myelodysplastic syndrome (appendix p 4). Follow-up time between diagnosis of first primary cancer and diagnosis of second primary cancer did not systematically affect risk of developing a second primary cancer; we noted significantly increased risks of a second primary cancer after myeloid neoplasia in most follow-up periods (appendix p 5). For all patients with myelo dysplastic syndrome, maximal follow up was relatively short at 30 years (ie, 1986-2015). We analysed relative risks of a second primary cancer after chronic myeloid leukaemia in more detail, because standard treatment for chronic myeloid leukaemia changed with the introduction of tyrosine kinase inhibitors around the year 2000 (appendix p 6). Although few second primary cancers were recorded in this analysis, we noted significant increases in the risk of upper aerodigestive tract, thyroid, and connective tissue cancers as second primary cancers in the period between 2001 and 2015 relative to the background risk of these cancers as first primaries between 2001 and 2005. Table 3 shows the RRs of a second primary cancer after a myeloid cancer, and of myeloid cancer as a second primary cancer. Overall, the relative risk of second primary cancer after all myeloid cancers was increased 1·36 (95% CI 1·30-1·42) times relative to the background risk of any first primary cancer diagnosis. An increased risk was shown for 15 cancer sites, notably for nasal cancer (RR 3·10, 95% CI 1·61-5·97), squamous cell skin cancer (2·80, 2·50-3·14), and Hodgkin lymphoma (2·63, 1·59-4·37). These RRs were significant at the 0·1% level. Myeloid cancer as a second primary cancer showed an RR of 1·32 (95% CI 1·28-1·37). Individually, (table 3) . Table 4 shows the RRs of all non-myeloid second primary cancers after a first diagnosis of acute myeloid leukaemia, chronic myeloid leukaemia, myelo dysplastic syndrome, or myeloproliferative neoplasm. The overall RRs for second primary cancers after each of these four diseases were 1·29 (95% CI 1·17-1·41), 1·52 (1·35-1·69), 1·42 (1·26-1·59), and 1·37 (1·30-1·43), respectively. The numbers of individual non-myeloid second primary cancers with increased RRs were 8 for acute myeloid leukaemia, 7 for chronic myeloid leukaemia, 8 for myelodysplastic syndrome, and 12 for myeloproliferative neoplasm. Risk of upper aerodigestive tract cancer, skin squamous cell carcinoma, and non-Hodgkin lymphoma was increased irrespective of myeloid primary type. Risk of kidney cancer was increased in patients with a first primary cancer diagnosis of chronic myeloid leukaemia, myelodysplastic syndrome, and myelopro liferative neoplasm relative to the background risk. For acute myeloid leukaemia, high RRs were noted for anal cancer (RR 3·92, 95% CI 1·26-12·16) and Hodgkin's lymphoma (3·60, 1·35-9·60). The RR for skin squamous cell carcinoma was 5·54 (95% CI 4·16-7·37) after chronic When comparing RRs between cancer-pairs between tables 4 and 5, we noted bi-directionally increased RRs for acute myeloid leukaemia with six cancers, for chronic myeloid leukaemia two cancers, for myelodysplastic syndrome with four cancers, and for myeloproliferative neoplasm with four cancers. The RRs for both reciprocal associations of acute myeloid leukaemia and haematological cancers and anal cancer were high.
We assessed RRs for second primary cancers after different subtypes of myeloproliferative neoplasm. The overall RRs for diagnosis of any second primary cancer after polycythaemia vera, essential thrombocythaemia, myelofibrosis, or myeloproliferative neoplasm (not otherwise specified) were 1·34 (95% CI 1·25-1·43), 1·39 (1·27-1·54), 1·88 (1·64-2·17), and 1·50 (1·28-1·76), respectively, compared with risk of any first primary cancer ( myelo fibrosis were both associated with increased risk of seven secondary primary cancers; and myeloproliferative neoplasm (not otherwise specified) was associated with increased risk of developing second primary cancer at nine cancer sites relative to the background rates for these cancers. All myeloproliferative neoplasms were associated with an increased risk of developing skin squamous cell carcinoma as a second primary cancer, with the greatest risk after myelofibrosis (RR 3·71, 95% CI 2·27-6·05). Relative risks of nervous system cancer were increased after polycythaemia vera, essential thrombocythaemia, and myelofibrosis; risks of non-Hodgkin lymphoma were increased after polycythaemia vera, myelofibrosis, and myeloproliferative neoplasm (not otherwise specified). Risk of other female genital cancers (RR 3·31, 95% CI 1·38-7·96) was increased only in patients who had had essential thrombocythaemia. Risk of Hodgkin's lymphoma (RR 12·26, 95% CI 3·95-18·03) was increased in patients with previous myelofibrosis. We assessed the risk of myelioproliferative neoplasms as second primary cancers after other cancers (appendix p 7). With the exception of kidney and thyroid cancers, no other cancers were observed to have increased risk throughout most of the subtypes of myeloproliferative neoplasms. We noted we noted reciprocal associations confirming increased bi-directional risk for six unique cancer-myeloproliferative neoplasm pairs (melanoma, kidney, and connective tissue cancer paired with 
Discussion
To address a paucity of data regarding the development of second primary cancers after myeloproliferative neoplasms, we used data from the Swedish Cancer Registry to analyse all myeloid cancers and second primary cancers in Sweden, and myeloid cancers diagnosed as second primary cancers after any non-leukaemic first cancer, between 1958 and 2015. Our analysis provides further evidence that survivorship from a myeloid cancer is associated with a statistically significant relative risk of a second primary cancer. We showed that the increased relative risk is not confined to any one myeloid cancer, and is also increased after myelodysplastic syndrome. The relative risk of upper aerodigestive tract cancer, skin squamous cell carcinoma, and non-Hodgkin lymphoma were the major second primary cancers after previous acute myeloid leukaemia, chronic myeloid leukaemia, myelodysplastic syndrome, and myeloproliferative neoplasm. Our results thus provide new systematically analysed information on the risk of diverse types of second primary cancers, and validate and expand previous observations. 9,10,12-15 A major strength of our study, as compared with other analyses, is the avoidance of ascertainment bias in patient selection by using a registry that includes data from the entire Swedish population, with high proportions of case registration and long-term follow up. To the best of our knowledge, this is the first study to apply systematic bidirectional analysis for second primary cancer after myeloid cancer and myeloid cancer as second primary cancer. We used data from the largest population of myeloid neoplasms yet published. 9 The limitations include unavailability of some myeloid neoplasms before year 1993 and no information on treatment, in addition to the inherent weaknesses of observational studies in deducing disease causation. Although the coverage of the Swedish Cancer Registry is high, it might not be equally high for some newly established diagnostic categories, such as myelodysplastic syndrome. Other factors that are difficult to control for are reporting practices of second primary cancers.
Treatment-related side-effects are generally considered to be the cause of many second primary cancers following treatment for a myeloid cancer. 20 However, such a mechanism is unlikely to be the sole cause for all second primary cancers; there might be several mechanisms underlying the increased risk of a second primary cancer risk in patients who have had myeloid cancer. Although treatment for the myeloid cancers is heterogeneous and has changed over time, many patients-and certainly those in our cohort diagnosed before the year 2000-are likely to have received one or more types of cytoreductive treatment during their disease course. 4, 21 Hydroxyurea has been used as first line cytoreductive treatment for myeloproliferative neoplasm in many patients. An increased risk of non-melanoma skin cancer during hydroxyurea treatment has been reported, and people have hypothesised that hydroxyurea could act as a photosensitiser and thus, in combination with ultraviolet radiation exposure, increase the risk of skin squamous cell carcinoma. 22 However, this mechanism is not likely to be the cause of a myeloproliferative cancer that develops after a first primary skin squamous cell carcinoma because this type of skin cancer is usually treated by surgery. By contrast, side-effects of other chemotherapeutic agents such as anthracyclines might have contributed to the increased risk of second primary cancers after myeloid neoplasia, such as in cases of lung and upper aerodigestive tract cancers. We showed a possible increase in relative risk in cases with upper aerodigestive tract cancer after chronic myeloid leukaemia diagnosed between 2001 and 2015 as compared with the earlier study periods, which a previous small Swedish study suggested might have been associated with the use of tyrosine kinase inhibitors. 10 We noted that testicular cancer was associated with an increased risk of acute myeloid leukaemia, chronic myeloid leukaemia, and myelodysplastic syndrome. Testicular cancer is treated with radiotherapy and a combination of drugs that damage DNA, such as bleomycin, etoposide, and cisplatin, which might be an explanation for the increased risk of second myeloid neoplasia. 23 In this study, myeloid neoplasms were associated with all haematological cancers that might have had acquired immune dysfunction due to cytotoxic treatment or bone marrow transplantation as an underlying mechanism. 24 Inherited mechanisms might also contribute to the development of myeloid neoplasms through master regulators of haemopoiesis, including transcriptional regulators of critical steps in cell development such as STAT5, CEBPα, PU.1, and CITED2, among others. 25 Their expression is controlled at the genetic or epigenetic level, and aberrations in their expression might have pleiotropic effects on several cell lineages. For example, loss of the genetic regulator GATA-2 has been shown to suppress haemopoiesis and contribute to immunodeficiency. 26 Changes in the expression of other epigenetic regulators, such as IDH, TET2, and BCAT1 genes, might have similar effects. 27 Given that many cancer susceptibility genes have pleiotropic effects it is plausible that the risk of a second primary cancer is influenced by inherited genetic factors, either through high penetrance alleles or co-inheritance of multiple common risk variants. Patients with myeloid neoplasia have an increased risk of non-haematological cancers prior to their diagnosis of myeloproliferative neoplasm, and first-degree relatives of patients with myeloproliferative cancer have an increased risk of myeloproliferative neoplasms and chronic lymphocytic leukaemia-as well as melanoma and brain cancer-which is consistent with germline susceptibility to myeloproliferative and other cancers. 28, 29 Although risks of other cancers in families of patients with myeloid neoplasia are yet to be established, common genetic variants of TERT associated with risk of myeloproliferative neoplasia have also been shown to influence glioma and other cancers. 30 Familial risks might also be a contributing factor. We have previously published the results of a study of discordant associations between all common cancers using data from the Swedish Family-Cancer Database, and shown that discordant familial risks do exist but RRs are small, in the order of 1·1-1·2 for most cancer pairs. 31 On the other hand, because myeloid diseases and their treatment can be associated with immunosuppression, this raises the possibility that impaired tumour immunosurveillance could play a part in the development of second primary cancers in patients with previous myeloid cancer. 24 The contribution of immune dysfunction in these cancers might be compounded by germline susceptibility. For example, germline mutations in GATA2 have been reported to contribute to immune deficiency in haematological cancers, including familial myelodysplastic syndrome and acute myeloid leukaemia. 32 We have provided evidence of bi-directional associations between myeloid cancers and lymphomas, and between lymphomas and skin squamous cell carcinoma, kidney cancer, and bladder cancer. Increased risk of second primary cancer in patients with myeloid cancer is probably multifactorial. A combination of cytoreductive treatment, genetic predisposition, and immune-related effects might all contribute to an increased cancer risk in survivors of myeloid cancers.
In conclusion, we have provided a comprehensive analysis of cancer risks associated with myeloid cancers using observational data from a comprehensive cancer registry. We propose putative mechanisms that might contribute to these associations, such as immune disturbances acting together with cytotoxic and genetic effects. Future studies are clearly warranted to investigate such potential mechanisms in detail-for example, by assessing immune competence as a predictor of second primary cancer, and the effects of immunotherapy on the risk of second primary cancers. Our findings substantiate the well-known risks of developing second primary cancers after surviving each of the myeloid cancers, and help inform the long-term management of patients successfully treated for these tumours, who should be monitored for the occurrence of second primary cancers.
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